|
|
|
|
|
Misoprostol
drug data and news
Misoprostol drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Misoprostol | ||
| Brand Names/Synonyms | Arthrotec; Cytotec; MISOPROSTOL 1 : 100 HPMC DISPERSION; Misoprostol; Misoprostol 1:100; Misoprostol [Usan:Ban:Inn:Jan]; Misoprostolum [Inn-Latin] | ||
| Indication | Indicated for the treatment of ulceration (duodenal, gastric and NSAID induced) and prophylaxis for NSAID induced ulceration. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Misoprostol is a prostaglandin E1 (PGE1) analogue used for the treatment and prevention of stomach ulcers. When administered, misoprostol stimulates increased secretion of the protective mucus that lines the gastrointestinal tract and increases mucosal blood flow, thereby increasing mucosal integrity. It is sometimes co-prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) to prevent the occurrence of gastric ulceration, a common adverse effect of the NSAIDs. | ||
| Mechanism Of Action | Misoprostol seems to inhibit gastric acid secretion by a direct action on the parietal cells through binding to the prostaglandin receptor. The activity of this receptor is mediated by G proteins which normally activate adenylate cyclase. The indirect inhibition of adenylate cyclase by Misoprostol may be dependent on guanosine-5’-triphosphate (GTP). The significant cytoprotective actions of misoprostol are related to several mechanisms. These include: 1. Increased secretion of bicarbonate, 2. Considerable decrease in the volume and pepsin content of the gastric secretions, 3. It prevents harmful agents from disrupting the tight junctions between the epithelial cells which stops the subsequent back diffusion of H+ ions into the gastric mucosa, 4. Increased thickness of mucus layer, 5. Enhanced mucosal blood flow as a result of direct vasodilatation, 6. Stabilization of tissue lysozymes/vascular endothelium, and 7. Improvement of mucosal regeneration capacity. | ||
| Misoprostol News (When available) |
A Diversifying Purdue Pharma Hopes to Regain Control of Its ... 07 Mar 2006 The Effects of Tramadol and Fentanyl on Gastrointestinal Motility ... Feb 21, 2006 TheraQuest's Abuse Deterrent Tramadol ER IND for Neuropathic Pain ... Feb 6, 2006 Cipher reports fiscal 2005 year-end results Mar 2, 2006 Moderate To Moderately-severe Chronic Pain - Once Daily ULTRAM® ... Feb 27, 2006 Once Daily ULTRAM(R) ER Extended-Release Tablets Now Available in ... Feb 21, 2006 Labopharm Reports Results for Fourth Quarter Fiscal 2005 Feb 16, 2006 Once Daily ULTRAM(R) ER Extended-Release Tablets Now Available in ... Feb 21, 2006 Labopharm Reports Results for Fourth Quarter Fiscal 2005 Feb 16, 2006 Biovail's pain drug released in US Feb 21, 2006 Labopharm appoints Santo J. Costa to Board of Directors Mar 2, 2006 Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006 A pain in the neck Feb 24, 2006 Par Pharmaceutical Reports Sales and Earnings for 2005 Feb 28, 2006 Sublingual Piroxicam for Postoperative Analgesia: Preoperative ... Feb 21, 2006 Recordati: 2005 Accounts Approved by the Board. Dividend ... Mar 2, 2006 Notice of Cipher Pharmaceuticals Inc. Conference Call Feb 28, 2006 Penwest pain drug posts encouraging results Feb 13, 2006 Labopharm (TSX: DDS) has $11.1 million loss in Q4 as sales ... Feb 16, 2006 Meda AB (publ): Year-End 2005 Report Feb 22, 2006 Crime Reports for Feb. 17 — Feb. 20 Feb 22, 2006 Labopharm to present at Merrill Lynch global healthcare conference ... Feb 1, 2006 Student teacher faces drug rap Feb 19, 2006 VASSALBORO Police arrest man, seize drugs, cash Feb 11, 2006 Drug search yields arrest, confiscations Feb 13, 2006 Penwest Reports Positive Results For Phase IIa Trial of PW4142 Feb 10, 2006 Labopharm To Host Conference Call Thursday, February 16, 2006 At 8 ... Feb 9, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Oxytocics; Anti-ulcer Agents; Abortifacient Agents; Prostaglandins; ATC:A02BB01 | ||
| Absorption | Misoprostol is extensively absorbed. | ||
| Interactions | Interactions for Misoprostol: Misoprostol has not been shown to interfere with the beneficial effects of aspirin on signs and symptoms of rheumatoid arthritis. Misoprostol does not exert clinically significant effects on the absorption, blood levels, and anti-platelet effects of therapeutic doses of aspirin. Misoprostol has no clinically significant effect on the kinetics of diclofenac or ibuprofen. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | methyl7-[3-hydroxy-2-(4-hydroxy-4-methyl-oct-1-enyl)-5-oxo-cyclopentyl]heptanoate | ||
| Chemical Formula | C22H38O5 | ||
| Molecular Weight | 382.534 g/mol | ||
| Smiles String | CCCCC(C)(CC=CC1C(CC(=O)C1CCCCCCC(=O)OC)O)O | ||
| Melting Point | Not Available | ||
| Water Solubility | >1.6 mg/ml at 25.0 oC | ||
| State | Liquid | ||
| LogP/Hphobicity | 3.366 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Rapidly de-esterified to misoprostol acid. The de-esterified metabolite undergoes further metabolism by beta and omega oxidation; oxidation is followed by reduction of the ketone to yield prostaglandin F analogs. | ||
| Half Life | 20-40 minutes | ||
| Protein Binding [%] | 85% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Misoprostol.html http://www.rxlist.com/cgi/generic/misopro.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00037 | ||
| CAS Registry Number | 59122-46-2 | ||
| KEGG Compound ID | C07227 | ||
| PubChem ID | SID:183429 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2248846 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |